{
  "@context": "https://schema.org/",
  "@type": "Dataset",
  "id": "metabolic:rapamycin-alternative-long-gen-0659:longevity:v1",
  "title": "Rapamycin Alternative Long Gen 0659 â€” Longevity",
  "category": "longevity",
  "tier": "Black",
  "label": "FAIL",
  "P_effect_gt_delta": 0.9999,
  "gate_results": {
    "phi": "FAIL",
    "r": 0.9,
    "j": 0.0,
    "k": "PASS",
    "l": "PASS"
  },
  "evidence_summary": {
    "n_studies": 3,
    "total_n": 398,
    "I2": 0.0,
    "tau2": 0.0,
    "mu_hat": 0.32451,
    "mu_CI95": [
      0.224183,
      0.424837
    ],
    "design_breakdown": {
      "RCT": 3,
      "cohort": 0,
      "other": 0
    }
  },
  "policy_refs": {
    "tel5_levels": "v1.2.0",
    "monte_carlo": "v1.0.1-reml-grid",
    "journal_trust": "2025-10-30"
  },
  "version": "v1",
  "policy_fingerprint": "0x6036438e1b958d88",
  "tier_label_system": "TEL-5",
  "created": "2025-11-06T07:16:50.747581+00:00",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "bibtex": "@techreport{tervyx2025, title={TERVYX Protocol v1.0}, author={Kim, Geonyeob}, year={2025}}",
  "csl_json": {
    "type": "report",
    "title": "TERVYX Protocol v1.0",
    "author": [
      {
        "family": "Kim",
        "given": "Geonyeob"
      }
    ],
    "issued": {
      "date-parts": [
        [
          2025
        ]
      ]
    }
  },
  "references": [
    {
      "@id": "doi:10.1234/rapamycin-alternative-long-gen-0659-01",
      "@type": "ScholarlyArticle",
      "identifier": "doi:10.1234/rapamycin-alternative-long-gen-0659-01",
      "studyIds": [
        "LONG-GEN-0659_01"
      ],
      "citation": "LONG-GEN-0659_01 (2018); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with nad boosting concerns; Outcome: nad_boosting; DOI: 10.1234/rapamycin-alternative-long-gen-0659-01; Adverse Events: None reported.",
      "doi": "10.1234/rapamycin-alternative-long-gen-0659-01",
      "sameAs": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-01",
      "datePublished": "2018",
      "isPartOf": {
        "@type": "Periodical",
        "name": "longevity_journal"
      }
    },
    {
      "@id": "doi:10.1234/rapamycin-alternative-long-gen-0659-02",
      "@type": "ScholarlyArticle",
      "identifier": "doi:10.1234/rapamycin-alternative-long-gen-0659-02",
      "studyIds": [
        "LONG-GEN-0659_02"
      ],
      "citation": "LONG-GEN-0659_02 (2019); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with nad boosting concerns; Outcome: nad_boosting; DOI: 10.1234/rapamycin-alternative-long-gen-0659-02; Adverse Events: None reported.",
      "doi": "10.1234/rapamycin-alternative-long-gen-0659-02",
      "sameAs": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-02",
      "datePublished": "2019",
      "isPartOf": {
        "@type": "Periodical",
        "name": "longevity_journal"
      }
    },
    {
      "@id": "doi:10.1234/rapamycin-alternative-long-gen-0659-03",
      "@type": "ScholarlyArticle",
      "identifier": "doi:10.1234/rapamycin-alternative-long-gen-0659-03",
      "studyIds": [
        "LONG-GEN-0659_03"
      ],
      "citation": "LONG-GEN-0659_03 (2020); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with nad boosting concerns; Outcome: nad_boosting; DOI: 10.1234/rapamycin-alternative-long-gen-0659-03; Adverse Events: None reported.",
      "doi": "10.1234/rapamycin-alternative-long-gen-0659-03",
      "sameAs": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-03",
      "datePublished": "2020",
      "isPartOf": {
        "@type": "Periodical",
        "name": "longevity_journal"
      }
    }
  ],
  "citations_manifest_hash": "sha256:1828ffa5ea4682eb23ead4f28176eb3f19b487f180bd547a484363f8192c1788",
  "audit_hash": "0xd478192fd82425bb"
}
